# Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-ustekinumab-an-il-12-and-il-23-inhibitor-in-patients-with/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Ronald van Vollenhoven,Bevra H. Hahn,George C. Tsokos,Carrie Wagner,Peter E. Lipsky,Zahi Touma,Victoria P. Werth,Robert Gordon,Bei Zhou,Benjamin Hsu,Marc Chévrier,Manon Triebel,Jarrat Jordan,Shawn Rose |
| Citations | 326 |
| DOI | 10.1016/s0140-6736(18)32167-6 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2890532892 |
| PMID | 30249507 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Ronald van Vollenhoven](https://scholariq.org/researchers/ronald-van-vollenhoven/)
- [Victoria P. Werth](https://scholariq.org/researchers/victoria-p-werth/)
- [Zahi Touma](https://scholariq.org/researchers/zahi-touma/)
- [Peter E. Lipsky](https://scholariq.org/researchers/peter-e-lipsky/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)

## Paper topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.